REVVITY, INC Payments to Acquire Marketable Securities
REVVITY, INC (RVTY) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-02-24
- REVVITY, INC payments to acquire marketable securities for the quarter ending 2024-12-29 was $0.00, a 100.00% decline year-over-year.
- REVVITY, INC payments to acquire marketable securities for the quarter ending 2024-09-29 was $0.00.
- REVVITY, INC payments to acquire marketable securities for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- REVVITY, INC payments to acquire marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- REVVITY, INC payments to acquire marketable securities for fiscal 2025 was $0.00.
- REVVITY, INC payments to acquire marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- REVVITY, INC payments to acquire marketable securities for fiscal 2023 was $1.22B.
- REVVITY, INC payments to acquire marketable securities for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-28 | $0.00 10-K · filed 2026-02-24 | |||
| 2024-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $390.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $390.39M derived: sum of 3 quarters · filed 2026-02-24 | $390.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $390.39M derived: sum of 2 quarters · filed 2026-02-24 | $390.39M derived: sum of 3 quarters · filed 2026-02-24 | $1.03B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $390.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $390.39M derived: sum of 2 quarters · filed 2026-02-24 | $1.03B derived: sum of 3 quarters · filed 2026-02-24 | $1.22B 10-K · filed 2026-02-24 |
| 2023-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $637.76M derived: sum of 2 quarters · filed 2024-11-06 | $831.22M 10-Q · filed 2024-11-06 | |
| 2023-07-02 | $637.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $831.22M 10-Q · filed 2024-08-06 | ||
| 2023-04-02 | $193.45M 10-Q · filed 2024-05-07 | |||
| 2023-01-01 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |